Stock Events

Stock Events

Hybrigenics 

€0.008900
26
+€0.00+8.54% Friday 15:05

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

15MayExpected
Q3 2017
Q1 2024
Q2 2024
Q4 2024
Q1 2026
-0.17
0.16
0.5
0.83
Expected EPS
N/A
Actual EPS
N/A

Financials

-31.96%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
38.86MRevenue
-12.42MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology company that competes in developing innovative therapies, similar to Hybrigenics' focus on cancer and other diseases.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the research and development of therapeutic products in areas like oncology, competing directly with Hybrigenics' cancer treatment efforts.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is a global biopharmaceutical company with a strong emphasis on cancer research and treatments, directly competing with Hybrigenics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company with a broad range of products, including in oncology, making it a competitor to Hybrigenics.
Merck
MRK
Mkt Cap366B
Merck & Co. focuses on cancer drugs and vaccines, which puts it in direct competition with Hybrigenics in the oncology sector.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that has a significant presence in the oncology market, competing with Hybrigenics.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a leader in oncology, directly competing with Hybrigenics in the development of cancer treatments.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, making it a competitor to Hybrigenics.
Sanofi
SNY
Mkt Cap107.39B
Sanofi is a global healthcare leader that offers treatments in oncology, competing with Hybrigenics in the cancer treatment space.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is a global pharmaceutical company that has a focus on oncology, competing with Hybrigenics in developing cancer treatments.

About

Hybrigenics SA, together with its subsidiaries, operates as a biotechnology company in France. The company engages in development of biotechnology in the field of biotechnology, oncology, regenerative medicine, and anti-aging medicine. It is also involved in the development of technical solutions using adipose tissue cells and stem cells. The company is headquartered in Gallargues-le-Montueux, France. Hybrigenics SA is a subsidiary of Diagnostic Medical Systems S.A.
Show more...
CEO
Country
France
ISIN
FR0004153930
WKN
000A0M9ZU

Listings

STU
DE
3HB.STU
F
DE
3HB.F
MU
DE
3HB.MU
KQ
KR
158430.KQ

0 Comments

Share your thoughts

FAQ

What is Hybrigenics stock price today?▼
The current price of ALHYG.PA is €0.01 EUR — it has increased by +8.54% in the past 24 hours. Watch Hybrigenics stock price performance more closely on the chart.
What is Hybrigenics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Euronext Paris exchange Hybrigenics stocks are traded under the ticker ALHYG.PA.
What is Hybrigenics revenue for the last year?▼
Hybrigenics revenue for the last year amounts to 38.86M EUR.
What is Hybrigenics net income for the last year?▼
ALHYG.PA net income for the last year is -12.42M EUR.
In which sector is Hybrigenics located?▼
Hybrigenics operates in the Health & Wellness sector.
When did Hybrigenics complete a stock split?▼
Hybrigenics has not had any recent stock splits.
Where is Hybrigenics headquartered?▼
Hybrigenics is headquartered in Gallargues-le-Montueux, France.